



Professor Sir Peter Horby, Professor Sir Martin Landray RECOVERY trial Co-chairs Nuffield Department of Population Health Oxford

4<sup>th.</sup> March 2022

Dear Peter and Martin

## **RECOVERY trial DMC report**

Today we reviewed the RECOVERY trial safety and efficacy data that were available for patients randomised by 28<sup>th</sup> February 2022.

For the interventions still in active recruitment, the numbers of adults included in the comparison of each agent with its control were respectively: high dose steroids (1404), empagliflozin (3431), sotrovimab (568) and molnupiravir (175). The dataset included 5 women who were pregnant at entry and 3 children.

In the light of the available trial data and all relevant external information, we saw no cogent reason to modify the protocol or intake to the study.

The full DMC will next meet to review the safety and efficacy data for all treatments on 10<sup>th</sup> June 2022. There will be a Chairman's review on 6<sup>th</sup> May 2022.

Yours sincerely

Ronder-

Professor Peter Sandercock, MA, DM, FRCPE, FESO, FWSO Chairman RECOVERY trial DMC Emeritus Professor of Medical Neurology, Centre for Clinical Brain Sciences

Cc DMC members, RECOVERY trial office.

Professor M Dennis Professor A Farrall Professor S Grant Professor J Ironside Professor R Knight Professor S Lawrie Professor A McIntosh Professor M Macleod Professor I Marshall Professor D Owens Professor C Ritchie Professor P Sandercock Professor R Sellar Professor C Smith Professor C Sudlow Professor L Thomson Professor A Waldman Professor J Wardlaw Professor R Will

The University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK t: +44 (0)131 465 9602 / w: www.ccbs.ed.ac.uk / e:<u>Peter.sandercock@ed.ac.uk</u>